{"product_id":"cjc-1295-copy","title":"RETATRUTIDE (15mg)","description":"\u003cp class=\"MsoNormal\" style=\"margin-bottom: 9.0pt;\"\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eRetatrutide is a first-in-class triple agonist of GLP-1, GIP, and glucagon receptors currently in Phase 3 clinical trials. By simultaneously engaging three complementary metabolic receptor pathways, it has produced the most significant body weight reductions observed in peer-reviewed pharmacological research. Phase 2 data reported average weight reductions of up to 24% of body weight.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"margin: 6.0pt 0in 5.0pt 0in;\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 12.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial; color: #2e6da4;\"\u003eMechanism of Action\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eActivates GLP-1 receptors, studied for appetite reduction, delayed gastric emptying, and glucose-dependent insulin secretion.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eActivates GIP receptors, investigated for insulin release enhancement and potential adipose tissue lipolysis.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eActivates glucagon receptors, driving caloric expenditure and hepatic fatty acid oxidation in metabolic models.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eTriple agonism produces synergistic metabolic effects not observed with dual or single receptor agonism alone.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003ePreclinical and clinical research suggests direct reduction in hepatic fat content, relevant to NAFLD\/NASH biology.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"margin: 7.0pt 0in 5.0pt 0in;\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 12.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial; color: #2e6da4;\"\u003eResearch Areas\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eObesity and overweight pharmacology research with unmatched weight reduction observations to date.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eType 2 diabetes and comprehensive glycemic control studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eMetabolic syndrome research addressing multiple cardiometabolic risk factors simultaneously.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eNAFLD and NASH biology research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e        \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial;\"\u003eBody recomposition studies examining fat loss alongside muscle mass preservation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"margin: 7.0pt 0in 4.0pt 0in;\"\u003e\u003cb\u003e\u003cspan style=\"font-size: 12.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial; color: #2e6da4;\"\u003ePresentation and Storage\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"margin-bottom: 3.0pt;\"\u003e\u003ci\u003e\u003cspan style=\"font-size: 11.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: Arial; color: #444444;\"\u003eSupplied as a lyophilized powder in a sealed vial containing 15mg of retatrutide. Reconstitute with bacteriostatic water for laboratory use. Store at -20C.\u003c\/span\u003e\u003c\/i\u003e\u003c\/p\u003e","brand":"bioreverselabs.com","offers":[{"title":"Default Title","offer_id":45880847204525,"sku":null,"price":1950.0,"currency_code":"MXN","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0761\/1577\/1565\/files\/100MG.png?v=1775534777","url":"https:\/\/bioreverselabs.com\/products\/cjc-1295-copy","provider":"Bio Reverse Labs","version":"1.0","type":"link"}